ERBB3 and neoplasm: Based on previous studies from our group and others demonstrating that elisidepsin downregulates the HER3 receptor tyrosine kinase and that high expression of HER3 is prevalent in a broad number of different tumor cells, we investigated if modulation of protein expression levels of the HER3 receptor affects sensitivity to elisidepsin in a panel of tumor cell lines with variable expression of this receptor.